Historically, the management of this tumour has been frustrating due to the lack of effective treatments; however, therapeutic options have improved over the past decade with the introduction of sirolimus, a mammalian target of rapamycin (mTOR) inhibitor [4]. This evidence concerns the gene MTOR and neoplasm.